Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2008

View Archived Issues

Novel nonpeptide motilin agonists under preclinical evaluation for gastric motility disorders

Allergan reports top-line results from phase III Botox migraine program

Argos starts phase II personalized immunotherapy trial in renal cell carcinoma

Evotec initiates phase II proof-of-concept EVT-302 trial in smoking cessation

Omeros enrolls patients in phase I/II OMS-302 trial in ophthalmologic surgery

Phase II diclofenac sodium patch trial achieves primary endpoint in acute pain

Phase III study demonstrates that Hexvix cystoscopy improves patient outcome

Proof-of-concept studies validate EthR inhibitors as ethionamide boosters in tuberculosis

MPP-021 series show analgesic effects in animal models of acute and neuropathic pain

Sciele and Addrenex present phase III results of Clonicel for ADHD

Calando initiates preclinical development for second siRNA oncology thereapeutic

E.U. approves Humira with methotrexate for juvenile idiopathic arthritis

Nanocarrier conjugate increases cisplatin delivery to local-regional tissues

FDA accepts Lundbeck's Serdolect NDA for review

Selective N-type calcium channel blocker APJ-2929 identified at Ajinomoto

MF-101 shows significant improvement in sleep disturbance from hot flashes

Recent sanofi-aventis patent reports new antiobesity compounds

NicOx's second naproxcinod phase III study meets primary efficacy endpoints

Novel anxiolytic agents disclosed in recent Bial-Portela patent

Unibioscreen and Drais to develop and commercialize UNBS-5162 for cancer

Recent patent literature covers new antidiabetic agents

Ariad to merge with Ariad Gene Therapeutics subsidiary

Isogenica licenses CIS display technology rights to Centocor

Dosing begins in phase II diabetes study of TT-223

Phase II sapacitabine trial in elderly AML patients expanded to include MDS patients

Keppra XR extended-release tablet approved in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...